Warfarin-dosing algorithm based on a population pharmacokinetic/ pharmacodynamic model combined with Bayesian forecasting

Tomohiro Sasaki, Hiroko Tabuchi, Shun Higuchi, Ichiro Ieiri

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aims: To develop a novel warfarin-dosing algorithm based on a previous population pharmacokinetic/ pharmacodynamic (PK/PD) model with Bayesian forecasting to facilitate warfarin therapy. Materials & methods: Using information on CYP2C9 and VKORC1 genotypes, S-warfarin level, dose and international normalized ratio (INR) of prothrombin time, individual PK (apparent clearance of S-warfarin [CLs]) and PD (concentration resulting in 50% of Emax [EC50]) parameters were determined by Bayesian forecasting for 45 Japanese patients. Maintenance doses were described by multiple linear regression using individually estimated PK/PD parameters and INR values. The validity of the model and a comparison with other dosing methods were evaluated by bootstrap resampling and a cross-validation method. Results: The plasma concentration of S-warfarin and INR were accurately predicted from individual PK/PD parameters. The following final regression model for maintenance dose was obtained; maintenance dose = 11.2 x CLs + 0.91 x EC 50 + 2.36 x INR - 9.67, giving a strong correlation between actual and predicted maintenance doses (r2 = 0.944). Bootstrap resampling and cross-validation showed robustness and a superior predictive performance compared with other dosing methods. On the other hand, the predictability without actual measurements (S-warfarin and INR values) and Bayesian inference was comparable to other dosing methods. Conclusion: A novel algorithm, based on the population PK/PD model combined with Bayesian forecasting, gave precise predictions of maintenance dose, leading to individualized warfarin therapy.

Original languageEnglish
Pages (from-to)1257-1266
Number of pages10
JournalPharmacogenomics
Volume10
Issue number8
DOIs
Publication statusPublished - Dec 2 2009

Fingerprint

Warfarin
International Normalized Ratio
Pharmacokinetics
Population
Prothrombin Time
Linear Models
Genotype
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Warfarin-dosing algorithm based on a population pharmacokinetic/ pharmacodynamic model combined with Bayesian forecasting. / Sasaki, Tomohiro; Tabuchi, Hiroko; Higuchi, Shun; Ieiri, Ichiro.

In: Pharmacogenomics, Vol. 10, No. 8, 02.12.2009, p. 1257-1266.

Research output: Contribution to journalArticle

@article{76eca10fa48145e1876eec28c4f9499f,
title = "Warfarin-dosing algorithm based on a population pharmacokinetic/ pharmacodynamic model combined with Bayesian forecasting",
abstract = "Aims: To develop a novel warfarin-dosing algorithm based on a previous population pharmacokinetic/ pharmacodynamic (PK/PD) model with Bayesian forecasting to facilitate warfarin therapy. Materials & methods: Using information on CYP2C9 and VKORC1 genotypes, S-warfarin level, dose and international normalized ratio (INR) of prothrombin time, individual PK (apparent clearance of S-warfarin [CLs]) and PD (concentration resulting in 50{\%} of Emax [EC50]) parameters were determined by Bayesian forecasting for 45 Japanese patients. Maintenance doses were described by multiple linear regression using individually estimated PK/PD parameters and INR values. The validity of the model and a comparison with other dosing methods were evaluated by bootstrap resampling and a cross-validation method. Results: The plasma concentration of S-warfarin and INR were accurately predicted from individual PK/PD parameters. The following final regression model for maintenance dose was obtained; maintenance dose = 11.2 x CLs + 0.91 x EC 50 + 2.36 x INR - 9.67, giving a strong correlation between actual and predicted maintenance doses (r2 = 0.944). Bootstrap resampling and cross-validation showed robustness and a superior predictive performance compared with other dosing methods. On the other hand, the predictability without actual measurements (S-warfarin and INR values) and Bayesian inference was comparable to other dosing methods. Conclusion: A novel algorithm, based on the population PK/PD model combined with Bayesian forecasting, gave precise predictions of maintenance dose, leading to individualized warfarin therapy.",
author = "Tomohiro Sasaki and Hiroko Tabuchi and Shun Higuchi and Ichiro Ieiri",
year = "2009",
month = "12",
day = "2",
doi = "10.2217/pgs.09.65",
language = "English",
volume = "10",
pages = "1257--1266",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Warfarin-dosing algorithm based on a population pharmacokinetic/ pharmacodynamic model combined with Bayesian forecasting

AU - Sasaki, Tomohiro

AU - Tabuchi, Hiroko

AU - Higuchi, Shun

AU - Ieiri, Ichiro

PY - 2009/12/2

Y1 - 2009/12/2

N2 - Aims: To develop a novel warfarin-dosing algorithm based on a previous population pharmacokinetic/ pharmacodynamic (PK/PD) model with Bayesian forecasting to facilitate warfarin therapy. Materials & methods: Using information on CYP2C9 and VKORC1 genotypes, S-warfarin level, dose and international normalized ratio (INR) of prothrombin time, individual PK (apparent clearance of S-warfarin [CLs]) and PD (concentration resulting in 50% of Emax [EC50]) parameters were determined by Bayesian forecasting for 45 Japanese patients. Maintenance doses were described by multiple linear regression using individually estimated PK/PD parameters and INR values. The validity of the model and a comparison with other dosing methods were evaluated by bootstrap resampling and a cross-validation method. Results: The plasma concentration of S-warfarin and INR were accurately predicted from individual PK/PD parameters. The following final regression model for maintenance dose was obtained; maintenance dose = 11.2 x CLs + 0.91 x EC 50 + 2.36 x INR - 9.67, giving a strong correlation between actual and predicted maintenance doses (r2 = 0.944). Bootstrap resampling and cross-validation showed robustness and a superior predictive performance compared with other dosing methods. On the other hand, the predictability without actual measurements (S-warfarin and INR values) and Bayesian inference was comparable to other dosing methods. Conclusion: A novel algorithm, based on the population PK/PD model combined with Bayesian forecasting, gave precise predictions of maintenance dose, leading to individualized warfarin therapy.

AB - Aims: To develop a novel warfarin-dosing algorithm based on a previous population pharmacokinetic/ pharmacodynamic (PK/PD) model with Bayesian forecasting to facilitate warfarin therapy. Materials & methods: Using information on CYP2C9 and VKORC1 genotypes, S-warfarin level, dose and international normalized ratio (INR) of prothrombin time, individual PK (apparent clearance of S-warfarin [CLs]) and PD (concentration resulting in 50% of Emax [EC50]) parameters were determined by Bayesian forecasting for 45 Japanese patients. Maintenance doses were described by multiple linear regression using individually estimated PK/PD parameters and INR values. The validity of the model and a comparison with other dosing methods were evaluated by bootstrap resampling and a cross-validation method. Results: The plasma concentration of S-warfarin and INR were accurately predicted from individual PK/PD parameters. The following final regression model for maintenance dose was obtained; maintenance dose = 11.2 x CLs + 0.91 x EC 50 + 2.36 x INR - 9.67, giving a strong correlation between actual and predicted maintenance doses (r2 = 0.944). Bootstrap resampling and cross-validation showed robustness and a superior predictive performance compared with other dosing methods. On the other hand, the predictability without actual measurements (S-warfarin and INR values) and Bayesian inference was comparable to other dosing methods. Conclusion: A novel algorithm, based on the population PK/PD model combined with Bayesian forecasting, gave precise predictions of maintenance dose, leading to individualized warfarin therapy.

UR - http://www.scopus.com/inward/record.url?scp=70649095262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649095262&partnerID=8YFLogxK

U2 - 10.2217/pgs.09.65

DO - 10.2217/pgs.09.65

M3 - Article

C2 - 19663670

AN - SCOPUS:70649095262

VL - 10

SP - 1257

EP - 1266

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 8

ER -